Immix Biopharma Inc (IMMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,886 | -9,737 | -5,331 | -15,596 | -10,440 |
| Depreciation Amortization | 74 | 48 | 24 | 6 | 2 |
| Accounts receivable | -747 | -815 | -912 | -893 | -428 |
| Other Working Capital | 1,378 | -975 | 537 | 1,653 | 229 |
| Other Operating Activity | 3,062 | 2,397 | 1,855 | 3,459 | 1,942 |
| Operating Cash Flow | $-13,119 | $-9,083 | $-3,827 | $-11,371 | $-8,694 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -671 | -399 | -302 | -52 | -39 |
| Investing Cash Flow | $-671 | $-399 | $-302 | $-52 | $-39 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 15,949 | 15,949 | 15,949 | 15,698 | 14,936 |
| Other Financing Activity | 0 | 0 | 0 | -235 | -60 |
| Financing Cash Flow | $15,949 | $15,949 | $15,949 | $15,464 | $14,877 |
| Exchange Rate Effect | 22 | -2 | -10 | 33 | 2 |
| Beginning Cash Position | 17,510 | 17,510 | 17,510 | 13,437 | 13,437 |
| End Cash Position | 19,690 | 23,975 | 29,319 | 17,510 | 19,582 |
| Net Cash Flow | $2,181 | $6,465 | $11,809 | $4,073 | $6,146 |
| Free Cash Flow | |||||
| Operating Cash Flow | -13,119 | -9,083 | -3,827 | -11,371 | -8,694 |
| Capital Expenditure | -671 | -399 | -302 | -52 | -39 |
| Free Cash Flow | -13,789 | -9,482 | -4,129 | -11,424 | -8,733 |